DEFA14A filed Nov 9, 2026 at 08:20 ET
Heron Therapeutics (HRTX) entered into a definitive Asset Purchase Agreement to sell substantially all of its assets to CorMedix Inc. for $145M in cash plus 14.6M CorMedix shares, contingent royalties on CINVANTI/SUSTOL sales above $25M in 2027-2029, and earn-out payments on ZYNRELEF sales in 2028. The deal requires HRTX stockholder approval, HSR clearance, and Nasdaq listing of the stock consideration. Supporting stockholders owning ~22% of HRTX shares have agreed to vote in favor. HRTX will retain its NOLs and the CorMedix shares received, and intends to remain publicly traded while evaluating strategic alternatives for the proceeds.